Results 151 to 160 of about 1,446 (206)
Accelerated Progression of Gait Impairment in Parkinson's Disease and REM Sleep Without Atonia
Annals of Clinical and Translational Neurology, Volume 13, Issue 3, Page 517-529, March 2026.ABSTRACT Objective People with Parkinson's disease (PD) and rapid eye movement (REM) sleep without atonia (RSWA) often have more severe gait disturbances compared to PD without RSWA. The association between the presence and expression of RSWA and the rate of progression of gait impairment in PD is unknown.
Sommer L. Amundsen‐Huffmaster +11 more
wiley +1 more source
Navigating the Ethereal Tightrope: The Nanogenerator Manipulates Neurons for Immune Equilibrium
Advanced Science, Volume 13, Issue 14, 9 March 2026.This review explores how nanogenerators modulate neuroimmune responses, offering innovative strategies for treating neurological disorders. By interfacing with neural pathways, they enable precise control of immune activity, especially via vagus nerve stimulation.
Jia Du +5 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Journal of Neural Transmission, 2019
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
R, Horowski, P-A, Löschmann
openaire +2 more sources
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
R, Horowski, P-A, Löschmann
openaire +2 more sources
Medical Clinics of North America, 1999
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Dopamine agonists have been used in the treatment of Parkinson's disease (PD) since the mid 1970s. With the approval of two new agents in 1997, the number available in the United States is up to four; bromocriptine, pergolide, pramipexole, ropinirole.
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2002
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire +2 more sources
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire +2 more sources
Dopamine agonist‐responsive depression
Psychogeriatrics, 2013AbstractDopaminergic dysfunction is implicated in the pathophysiology of treatment‐resistant depression. In this review, we describe the putative role of dopamine in depression, summarize the evidence for the efficacy of dopamine receptor agonists in the treatment of treatment‐resistant depression, and discuss the underlying mechanisms by which these ...
Hiroaki, Hori, Hiroshi, Kunugi
openaire +2 more sources
Neuroprotection by dopamine agonists
Journal of neural transmission. Supplementum, 1994Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents. Recent findings of impaired mitochondrial function, altered iron metabolism and increased lipid peroxidation in the substantia nigra of parkinsonian patients emphasize the significance of oxidative ...
Lange, Klaus W. +5 more
openaire +4 more sources
Dopamine agonists in Parkinson’s disease
Expert Opinion on Investigational Drugs, 2003Levodopa (LD), the immediate precursor of dopamine, is the most effective agent in the treatment of Parkinson's disease (PD). While quite successful in treating the primary motor deficits of PD, most patients eventually develop LD-related motor fluctuation, dyskinesias and other adverse effects associated with chronic LD therapy.
Ron, Tintner, Joseph, Jankovic
openaire +2 more sources
Neuroprotection and Dopamine Agonists
2004Parkinson’s disease is a neurodegenerative disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra pars compacta. Accumulating evidence indicates that apoptosis contributes to the cell death in Parkinson’s disease patients’ brain.
Zvezdan, Pirtosek, Dusan, Flisar
openaire +2 more sources